Neoplasia — MCQs

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 501: Which of the following features is NOT evaluated for the histological grading of breast carcinoma?

A. Tumor necrosis (Correct Answer)
B. Mitotic count
C. Tubule formation
D. Nuclear pleomorphism

Explanation: The histological grading of breast carcinoma is primarily performed using the **Nottingham Grading System** (also known as the Elston-Ellis modification of the Scarff-Bloom-Richardson scale) [1]. This system evaluates three specific morphological features to determine the aggressiveness of the tumor. ### Why Tumor Necrosis is the Correct Answer: **Tumor necrosis (Option A)** is a feature often seen in high-grade or aggressive tumors (especially the comedo subtype of DCIS), but it is **not** a formal component of the Nottingham Grading System [1]. While it may have prognostic significance, it is not assigned a numerical score during the grading process. ### Evaluation of Other Options (The Nottingham Criteria): The grading system assigns a score of 1 to 3 for each of the following three criteria [1]: * **Tubule Formation (Option C):** Evaluates how much of the tumor is organized into tubes or glands. More tubules indicate a lower grade (better differentiation) [1]. * **Nuclear Pleomorphism (Option D):** Assesses the variation in size and shape of the nuclei. Uniform nuclei score low, while highly irregular, enlarged nuclei score high [1]. * **Mitotic Count (Option B):** Measures the proliferation rate by counting the number of mitotic figures per 10 high-power fields (HPF) [1]. ### NEET-PG Clinical Pearls: * **Grading vs. Staging:** Remember that **Stage** (TNM) is generally a more powerful predictor of prognosis than **Grade** in breast cancer. * **Scoring:** The total score ranges from 3 to 9. * Grade I (Well-differentiated): 3–5 points. * Grade II (Moderately differentiated): 6–7 points. * Grade III (Poorly differentiated): 8–9 points. * **High-Yield Fact:** The Nottingham system is specifically used for **Invasive Carcinoma** (No Special Type/Ductal), not for In-situ lesions [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1068.

Question 502: CEA is elevated in all of the following conditions except:

A. Alcoholic cirrhosis
B. Ulcerative colitis
C. Carcinoma colon
D. Prostatic carcinoma (Correct Answer)

Explanation: **Explanation:** **Carcinoembryonic Antigen (CEA)** is a glycoprotein involved in cell adhesion. It is primarily produced during fetal development in the gastrointestinal tract and is normally present at very low levels in healthy adults. [1] **Why Prostatic Carcinoma is the correct answer:** CEA is not a marker for prostate cancer. The primary tumor markers for prostatic carcinoma are **PSA (Prostate-Specific Antigen)** [1], [2] and **Prostatic Acid Phosphatase (PAP)**. While CEA is a sensitive marker for various epithelial tumors (especially GI tract), it lacks the specificity required for prostate tissue. [1] **Analysis of Incorrect Options:** * **Carcinoma Colon:** CEA is the classic tumor marker for colorectal cancer. [1] While not used for screening (due to low specificity), it is the "gold standard" for **monitoring recurrence** and response to therapy. * **Ulcerative Colitis & Alcoholic Cirrhosis:** These represent **benign/inflammatory conditions** where CEA can be elevated. [1] NEET-PG often tests the fact that CEA is not cancer-specific. It can rise in smokers, patients with COPD, pancreatitis, inflammatory bowel disease (IBD), and liver cirrhosis. **High-Yield Clinical Pearls for NEET-PG:** * **Main Use:** CEA is used for **prognosis and monitoring** of colorectal, pancreatic, gastric, and breast carcinomas. [1] * **Non-Specific Nature:** Always remember that CEA can be elevated in **heavy smokers**. * **Fetal Origin:** It is an oncofetal antigen, meaning it is expressed in the fetus but suppressed after birth, only to reappear during neoplastic transformation. * **Prostate Marker Tip:** For NEET-PG, if a question mentions "Osteoblastic metastases" + "Prostate," the answer is usually PSA [2] or Alkaline Phosphatase. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 346. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 993-994.

Question 503: Which of the following pre-malignant conditions is associated with the highest probability of progression to malignancy?

A. Dysplasia
B. Hyperplasia
C. Leukoplakia
D. Erythroplakia (Correct Answer)

Explanation: **Explanation:** The correct answer is **Erythroplakia**. **Why Erythroplakia is the correct answer:** Erythroplakia is defined as a red, velvety, circumscribed area on the oral mucosa that cannot be characterized clinically or pathologically as any other condition. Among all oral premalignant lesions, it carries the **highest risk of malignant transformation**, exceeding 50%. Histologically, over 90% of erythroplakia cases demonstrate either severe dysplasia, carcinoma in situ, or invasive squamous cell carcinoma at the time of initial biopsy. This is due to the extreme thinning of the epithelium and increased vascularity, reflecting significant genetic instability. **Analysis of Incorrect Options:** * **Dysplasia:** While dysplasia is a disordered proliferation and a precursor to neoplasia, it is a histological description rather than a specific clinical entity. Its risk depends on the grade (mild, moderate, or severe) [1]. Erythroplakia is a clinical lesion that almost always harbors high-grade dysplasia. * **Hyperplasia:** This is an increase in the number of cells in an organ or tissue. Most hyperplasias (e.g., physiological or compensatory) are controlled processes and do not progress to cancer [1]. Only certain types of pathological hyperplasia (e.g., atypical endometrial hyperplasia) carry a significant risk. * **Leukoplakia:** This is a clinical term for a white patch [2]. While common, its malignant transformation rate is significantly lower (approximately 1% to 5%) compared to erythroplakia [2]. **NEET-PG High-Yield Pearls:** * **Speckled Leukoplakia (Erythroleukoplakia):** A clinical variant showing both white and red components; it has a higher risk than pure leukoplakia but lower than pure erythroplakia. * **Most common site for Erythroplakia:** Floor of the mouth, tongue, and soft palate. * **Rule of Thumb:** In the oral cavity, "Red is more dangerous than White." **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, pp. 746-747. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 344-345.

Question 504: The retinoblastoma gene regulates which phase transition?

A. G1 to S phase (Correct Answer)
B. G2 to M phase
C. G0 to S1 phase
D. S to G1 phase

Explanation: ### Explanation The **Retinoblastoma (RB) gene**, located on chromosome **13q14**, is the prototypical tumor suppressor gene. It acts as the "guardian of the G1-S checkpoint," controlling the cell's commitment to DNA replication [1]. **Why A is correct:** The RB protein exists in two states: 1. **Hypophosphorylated (Active):** In the G1 phase, RB binds to and sequesters the **E2F transcription factor**. This prevents the transcription of genes (like Cyclin E) required for DNA synthesis [1], [2]. 2. **Hyperphosphorylated (Inactive):** When the cell receives growth signals, Cyclin D-CDK4/6 complexes phosphorylate RB. This causes RB to release E2F, allowing the cell to transition from the **G1 to the S phase** [2]. Loss of RB function (via mutation) leads to uncontrolled entry into the S phase, a hallmark of neoplasia [1]. **Why incorrect options are wrong:** * **B (G2 to M):** This transition is primarily regulated by **Cyclin B-CDK1** (Mitosis Promoting Factor) and the DNA damage checkpoint involving **p53** and **CDC25**, not RB [3]. * **C (G0 to S1):** There is no "S1" phase. Cells move from G0 (quiescence) to G1 upon stimulation by growth factors [3]. * **D (S to G1):** This is the reverse of the normal cell cycle sequence. **High-Yield Clinical Pearls for NEET-PG:** * **Knudson’s Two-Hit Hypothesis:** Both alleles of the RB gene must be inactivated for tumor development [2]. * **Associated Tumors:** Germline mutations in RB1 predispose individuals to **Retinoblastoma** (often bilateral) and **Osteosarcoma** later in life. * **HPV Connection:** The **E7 oncoprotein** of High-risk Human Papillomavirus (HPV 16, 18) binds to and inactivates the RB protein, promoting cervical cancer [1]. * **Therapeutic Target:** CDK4/6 inhibitors (e.g., Palbociclib) are used in cancer therapy to keep RB in its active, growth-suppressing state. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 301-302. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 300-301. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. With Illustrations By, pp. 37-38.

Question 505: What percentage of medullary carcinoma of the breast presents with bilaterality?

A. Less than 5%
B. 10%
C. 20% (Correct Answer)
D. 50%

Explanation: **Explanation:** Medullary carcinoma of the breast is a distinct subtype of invasive ductal carcinoma, accounting for approximately 1-7% of all breast cancers. It is characterized by a well-circumscribed border, high-grade nuclei, and a prominent lymphoplasmacytic infiltrate [1]. **Why 20% is correct:** A defining clinical feature of medullary carcinoma is its higher propensity for **bilaterality** compared to other histological types. Approximately **20% of cases** present with bilateral involvement (either synchronous or metachronous). This is a high-yield fact for NEET-PG, as it contrasts with the typical 5-10% bilaterality seen in standard invasive ductal carcinoma (NOS). **Analysis of Incorrect Options:** * **A (<5%):** This is the typical rate of bilaterality for most common breast cancers, but it underestimates the specific incidence in medullary carcinoma. * **B (10%):** While closer to the average for Lobular Carcinoma (which is also known for bilaterality/multifocality), it is still lower than the reported incidence for Medullary Carcinoma. * **D (50%):** This is an overestimation. No common subtype of breast cancer presents with 50% bilaterality. **High-Yield Clinical Pearls for NEET-PG:** * **Triple Negative:** Medullary carcinomas are typically ER, PR, and HER2/neu negative (Triple Negative), yet they paradoxically have a **better prognosis** than standard invasive carcinomas [1]. * **BRCA1 Association:** There is a strong association between medullary carcinoma and **BRCA1 mutations**. * **Microscopic Hallmark:** "Pushing" borders (non-infiltrative) and syncytial growth patterns with no gland formation [1]. * **Differential:** It can mimic a fibroadenoma on imaging due to its circumscribed nature. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 455-456.

Question 506: Which of the following is included in the Modified Bloom Richardson criteria for Carcinoma Breast?

A. Desmoplasia
B. Lymphovenous embolism
C. Mitotic rate (Correct Answer)
D. All

Explanation: The **Modified Bloom-Richardson (MBR) grading system**, also known as the Nottingham Grading System, is the standard method used to determine the histological grade of breast carcinoma [1]. It is a semi-quantitative system that assesses the biological aggressiveness of a tumor based on three specific morphological features. ### Why Mitotic Rate is Correct: The MBR system assigns a score of 1 to 3 for each of the following three criteria [1]: 1. **Tubule Formation:** Percentage of the tumor forming definite tubules. 2. **Nuclear Pleomorphism:** Evaluation of the size and shape of the nuclei. 3. **Mitotic Count (Rate):** The number of mitoses per 10 high-power fields (HPF). The sum of these scores (ranging from 3 to 9) determines the Grade (I, II, or III) [1]. Therefore, **Mitotic rate** is a core component of this scoring system. ### Why Other Options are Incorrect: * **Desmoplasia (A):** This refers to the reactive fibrosis (stromal response) surrounding a tumor. While characteristic of invasive ductal carcinoma (giving it a "scirrhous" or hard feel), it is not a parameter used for histological grading. * **Lymphovenous Embolism (B):** The presence of tumor cells within lymphatic or vascular spaces is a critical prognostic factor for metastasis, but it is not part of the MBR grading criteria. ### High-Yield Clinical Pearls for NEET-PG: * **Grading vs. Staging:** Remember that MBR is a **Grading** system (microscopic), whereas TNM is a **Staging** system (clinical/extent). * **Prognostic Significance:** Grade III tumors (score 8-9) are poorly differentiated and have the worst prognosis [1]. * **Most Common Type:** Invasive Breast Carcinoma of No Special Type (NST), formerly called Invasive Ductal Carcinoma, is the most common type graded using this system [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1068-1069.

Question 507: Which of the following is NOT a characteristic typically observed in virus-induced tumor cells?

A. Loss of cellular orientation
B. Loss of contact inhibition
C. Changes in cell size (Correct Answer)
D. Formation of multicellular tumor spheroids

Explanation: **Explanation:** In the context of viral oncogenesis, the transformation of a normal cell into a neoplastic cell involves specific phenotypic changes. The question asks for the feature **NOT** typically characteristic of these transformed cells. **Why "Changes in cell size" is the correct answer:** While neoplastic cells often exhibit pleomorphism (variation in size and shape) [2], "changes in cell size" is a non-specific finding. In the specific context of viral transformation, the hallmark is not a mere change in size, but rather **immortality** and **uncontrolled proliferation** [3]. Transformed cells typically become smaller and more rounded (due to loss of cytoskeleton anchoring) rather than just "changing size." In many standardized pathology contexts, this is considered the least specific characteristic compared to the structural and behavioral shifts listed in the other options. **Analysis of Incorrect Options:** * **Loss of cellular orientation:** Transformed cells lose their polarity and organized arrangement, leading to a "disordered" growth pattern characteristic of malignancy. * **Loss of contact inhibition:** This is a cardinal feature of neoplastic cells. Normal cells stop dividing when they touch each other; virus-transformed cells continue to divide, piling up to form "foci" [1]. * **Formation of multicellular tumor spheroids:** Because transformed cells lose contact inhibition and anchorage dependence, they can grow in suspension or as three-dimensional aggregates (spheroids) rather than a simple monolayer. **NEET-PG High-Yield Pearls:** * **Anchorage Independence:** The ability of transformed cells to grow in semi-solid media (like agar) without attaching to a surface is a gold-standard laboratory test for neoplastic transformation. * **Viral Oncogenes:** Remember **v-onc** (viral) vs **c-onc** (cellular/proto-oncogenes). * **Key Viruses:** HPV (E6 inhibits p53; E7 inhibits Rb), EBV (LMP-1 mimics CD40), and HTLV-1 (Tax protein). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 232-233. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 278. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 212-213.

Question 508: Which gene is associated with apoptosis?

A. BCL-2 (Correct Answer)
B. BRAC
C. RET
D. All of the above

Explanation: **Explanation:** The correct answer is **BCL-2**. This gene belongs to a family of proteins that serve as the primary regulators of the **intrinsic (mitochondrial) pathway of apoptosis** [3]. **1. Why BCL-2 is correct:** BCL-2 is an **anti-apoptotic** gene located on chromosome 18. It stabilizes the mitochondrial membrane, preventing the release of Cytochrome C into the cytosol [2]. When BCL-2 is overexpressed (classically via the **t(14;18)** translocation in **Follicular Lymphoma**), cells fail to undergo programmed cell death, leading to tumor cell accumulation [1][4]. **2. Why other options are incorrect:** * **BRCA (BRCA1/BRCA2):** These are **Tumor Suppressor Genes** involved in DNA repair (specifically homologous recombination). Mutations are associated with breast, ovarian, and prostate cancers, but they do not directly regulate the apoptotic machinery. * **RET:** This is a **Proto-oncogene** that encodes a receptor tyrosine kinase. Mutations are linked to MEN 2A, MEN 2B, and Medullary Thyroid Carcinoma. It is involved in cell growth and differentiation signaling rather than the direct control of apoptosis. **High-Yield Clinical Pearls for NEET-PG:** * **Pro-apoptotic members:** BAX and BAK (form pores in the mitochondria) [2]. * **Anti-apoptotic members:** BCL-2, BCL-XL, and MCL-1 [2]. * **Pro-apoptotic BH3-only proteins:** BAD, BID, PUMA, and NOXA (sensors of cell stress) [5]. * **Guardian of the Genome:** p53 triggers apoptosis by upregulating BAX if DNA damage is irreparable [5]. * **Follicular Lymphoma Hallmark:** t(14;18) moves the BCL-2 gene to the IgH (Immunoglobulin Heavy chain) promoter site, causing its constitutive overexpression [1][4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 310-311. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 310. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 65-67. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 303-304.

Question 509: Leiomyoma is a tumor of which tissue type?

A. Cerebral tissue
B. Smooth muscle (Correct Answer)
C. Striated muscle
D. Cardiac muscle

Explanation: **Explanation:** The term **Leiomyoma** is derived from the Greek words *leios* (smooth), *mys* (muscle), and *-oma* (benign tumor). It is a benign mesenchymal tumor originating from **smooth muscle** cells [1]. 1. **Why Smooth Muscle is Correct:** Leiomyomas are most commonly found in the uterus (often referred to as "fibroids"), but they can also occur in the gastrointestinal tract, skin, and blood vessel walls [2]. Histologically, they are characterized by bundles of spindle-shaped cells arranged in a **whorled pattern** with "cigar-shaped" nuclei [3]. 2. **Why the Other Options are Incorrect:** * **Cerebral tissue:** Benign tumors of glial cells are rare; most are referred to as gliomas (though often malignant). A benign tumor of the meninges is a Meningioma. * **Striated (Skeletal) muscle:** A benign tumor of striated muscle is called a **Rhabdomyoma** [4]. * **Cardiac muscle:** While cardiac muscle is a type of striated muscle, a specific benign primary tumor of the heart is typically a **Myxoma** (most common) or a Rhabdomyoma (associated with Tuberous Sclerosis). **High-Yield Clinical Pearls for NEET-PG:** * **Uterine Leiomyoma:** The most common pelvic tumor in women [3]. It is **estrogen-dependent**, meaning it often enlarges during pregnancy and shrinks after menopause. * **Malignant Counterpart:** The malignant version of this tumor is a **Leiomyosarcoma** [2]. Note that Leiomyosarcomas typically arise *de novo* and not from pre-existing leiomyomas. * **Histology Tip:** Look for the "whorled" or "fascicular" arrangement of spindle cells. If you see "cross-striations" on microscopy, think Rhabdomyoma/sarcoma instead [4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 276-278. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1024-1025. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, p. 1024. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Bones, Joints, and Soft Tissue Tumors, p. 1222.

Question 510: Rosettes typically seen in Neuroblastoma are:

A. Flexner Wintersteiner rosettes
B. Homer-wright rosettes (Correct Answer)
C. Perivascular rosettes
D. Neurocytic rosettes

Explanation: ### Explanation **Correct Answer: B. Homer-Wright rosettes** **1. Why Homer-Wright rosettes are correct:** Homer-Wright (HW) rosettes are the hallmark histological feature of **Neuroblastoma**. These are "pseudorosettes" consisting of tumor cells arranged in a ring around a central space filled with **fibrillar eosinophilic material (neuropil)** [1]. Unlike true rosettes, they do not have a central lumen [1]. They are characteristic of primitive neuroectodermal tumors (PNETs), including Medulloblastoma and Ewing sarcoma. **2. Analysis of Incorrect Options:** * **A. Flexner-Wintersteiner rosettes:** These are "true rosettes" featuring a **central clear lumen** [2]. They are highly specific for **Retinoblastoma** and represent early photoreceptor differentiation [2]. * **C. Perivascular pseudorosettes:** These consist of tumor cells arranged around a **central blood vessel**. They are most characteristically seen in **Ependymomas** [3]. * **D. Neurocytic rosettes:** These are larger, more mature rosettes with a central area of fine neuropil, typically seen in **Central Neurocytoma**. **3. NEET-PG High-Yield Pearls:** * **Neuroblastoma:** Most common extracranial solid tumor of childhood [1]. It arises from neural crest cells (adrenal medulla or sympathetic chain). * **Biomarkers:** Elevated urinary catecholamines (VMA and HVA). * **Genetics:** **N-myc amplification** is the most important poor prognostic factor. * **Staging:** Stage 4S has a unique favorable prognosis (spontaneous regression). * **Histology Tip:** If you see "Neuropil" or "Small Round Blue Cells" in a pediatric abdominal mass, think Neuroblastoma [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 484-485. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Eye, p. 1342. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1312-1313.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?